Form 4: Greenwich LifeSciences Chief Medical Officer Awarded Stock Options

Frank Daugherty, Chief Medical Officer of Greenwich LifeSciences, was granted 104,890 stock options on December 24, 2024.

Summary

• Frank Daugherty, the Chief Medical Officer of Greenwich LifeSciences, was granted 104,890 stock options on December 24, 2024.
• The options have an exercise price of $12.16.
• 26,233 of the options vest immediately, with the remainder vesting monthly over 36 months.
• The vesting schedule is also dependent on the length of employment, with 10% vesting after 1-2 years, 20% after 2-3 years, 30% after 3-4 years, and the remainder after 4 years of employment.
• Following this transaction, Mr. Daugherty directly owns 209,780 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the Chief Medical Officer.
• The grant of options is a common practice to attract and retain key personnel.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• The vesting schedule could be a risk if the employee leaves before the options fully vest.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize and retain key executives.
• The vesting schedule described is typical, with a mix of immediate and time-based vesting to encourage long-term commitment.
• Comparable companies in the biotech sector often use similar equity compensation packages for their executive teams.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, equity compensation, insider trading, executive compensation, Greenwich LifeSciences, GLSI, Chief Medical Officer, Frank Daugherty